Clinical Trial Update: MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MIL62 in combination with Lenalidomide versus Lenalidomide alone for rituximab-refractory follicular lymphoma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Follicular Lymphoma and Marginal Zone Lymphoma | Phase 3 | Status: RECRUITING